Form 4: Corcept Therapeutics Executive Lyon Reports Stock Transactions

Joseph Douglas Lyon, Chief Accounting Officer of Corcept Therapeutics, reports stock transactions including share withholding for tax obligations, stock purchases, and vesting of restricted stock units.

Summary

• On March 1, 2024, Joseph Douglas Lyon, Chief Accounting Officer of Corcept Therapeutics, reported changes in beneficial ownership of the company's stock.
• The transactions included the withholding of 474 shares to cover tax obligations related to the vesting of restricted stock units at a price of $24.06 per share.
• Lyon also purchased 507 shares of Corcept Therapeutics common stock under a purchase plan at $24.06 per share.
• Additionally, 507 shares were acquired under unvested restricted stock awards granted through the purchase plan.
• Following these transactions, Lyon directly owns 7,314 shares of Corcept Therapeutics common stock, including unvested restricted stock awards.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.

Positives

• The purchase of shares by an executive could be seen as a positive signal about their confidence in the company's future.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock.

Key Dates